Rare Biomarkers Specimen Collection And Stabilization

Rare Biomarkers Specimen Collection And Stabilization Market Outlook

The global Rare Biomarkers Specimen Collection and Stabilization Market is poised to reach approximately USD 8 billion by 2035, growing at a compound annual growth rate (CAGR) of 12% from 2025 to 2035. This growth is primarily driven by the increasing prevalence of rare diseases and the rising demand for precision medicine, which requires accurate biomarkers for diagnosis and treatment. Additionally, advances in biotechnology and analytical techniques are enhancing the capabilities of specimen collection and stabilization processes, enabling more reliable and effective sample handling. The growing focus on personalized medicine and targeted therapies further propels the market, as healthcare providers seek better diagnostic tools to tailor treatments to individual patients. This dynamic landscape indicates a promising future for the rare biomarkers specimen collection and stabilization market.

Growth Factor of the Market

One of the critical growth factors contributing to the Rare Biomarkers Specimen Collection and Stabilization Market is the increasing investment in research and development by pharmaceutical companies and academic institutions. As the understanding of rare diseases improves, there is a corresponding rise in the development of diagnostic tests and therapies that rely on the accurate collection and stabilization of biological specimens. Moreover, the adoption of advanced technologies such as liquid chromatography and mass spectrometry in biomarker analysis is streamlining the specimen processing workflow, thereby enhancing the efficiency of research studies. The enhanced collaboration between diagnostic companies and healthcare providers ensures that new biomarker tests are quickly translated from research into clinical practice. Additionally, the growing awareness of personalized medicine is driving demand for novel biomarkers, necessitating the collection and stabilization of diverse specimen types for comprehensive testing. Overall, these interrelated factors are shaping a robust growth trajectory for the market.

Key Highlights of the Market

• The market is anticipated to grow at a CAGR of 12% from 2025 to 2035.
• Increasing prevalence of rare diseases significantly drives market growth.
• Technological advancements in biomarker analysis are enhancing specimen collection and stabilization.
• Rising focus on personalized medicine is influencing the demand for innovative biomarkers.
• Significant investments in R&D are accelerating the development of new diagnostic tools.

By Product Type

Blood-based Rare Biomarkers:

Blood-based rare biomarkers are pivotal in numerous diagnostic applications, as they often provide valuable insights into various health conditions. These biomarkers can be analyzed to detect abnormalities in cellular components, such as proteins and nucleic acids, which can indicate the presence of rare diseases. The collection process typically involves venipuncture, followed by stabilization methods to preserve the integrity of the biomarkers. The growing prevalence of chronic diseases and a demand for early detection methods contribute to the increasing utilization of blood-based biomarkers in clinical settings. Furthermore, advancements in blood testing technologies, including liquid biopsies, are enhancing the capabilities of blood-based biomarker analysis, further propelling this segment's growth.

Urine-based Rare Biomarkers:

Urine-based rare biomarkers are increasingly recognized for their non-invasive collection and significant diagnostic potential. These biomarkers provide valuable information regarding kidney function and systemic diseases, making them particularly useful in monitoring rare conditions. The collection of urine specimens is straightforward and can be conducted in various settings, enhancing patient compliance. Stabilization techniques for urine specimens, such as chemical preservatives, are crucial to maintaining biomarker integrity until analysis. The growing interest in urinary biomarkers in clinical research and diagnostics is driven by the need for non-invasive diagnostic methods and the rising prevalence of urological disorders, fueling the growth of this segment.

Saliva-based Rare Biomarkers:

Saliva-based rare biomarkers represent an innovative approach to disease detection due to their ease of collection and non-invasive nature. These biomarkers can reflect systemic health and physiological changes, making them suitable for monitoring a variety of health conditions, including rare diseases. The collection of saliva is particularly advantageous in pediatric populations where traditional blood collection methods may be challenging. Stabilization of saliva samples often involves temperature control and the addition of preservatives to prevent degradation. The increasing recognition of saliva as a valuable diagnostic medium in clinical research and practice is expected to drive the growth of saliva-based biomarkers in the market.

Tissue-based Rare Biomarkers:

Tissue-based rare biomarkers are crucial for understanding the pathology of rare diseases at a cellular level. The collection of tissue samples, often through biopsies, allows for detailed histopathological analysis, which can provide insights into the disease mechanism. The stabilization of tissue specimens is essential to preserve cellular morphology and biomarker integrity for subsequent analysis. This segment is driven by the increasing reliance on histological techniques in diagnosing rare cancers and other rare diseases. Furthermore, advancements in tissue preservation methods, such as cryopreservation and formalin fixation, are enhancing the usability of tissue samples in research and clinical settings.

Breath-based Rare Biomarkers:

Breath-based rare biomarkers are an emerging area of interest, utilizing volatile organic compounds (VOCs) in exhaled breath to diagnose diseases. This non-invasive collection method is attractive for patients, especially in pediatric and geriatric populations where conventional specimen collection may be challenging. Breath analysis has the potential to provide insights into metabolic and pathological processes, which can aid in the early detection of rare diseases. Stabilization methods for breath samples are still in developmental phases, but advancements in sensor technologies and analytical methods are paving the way for their clinical application. As research continues to uncover the diagnostic potential of breath-based biomarkers, this segment is expected to see significant growth.

By Application

Diagnostics:

The diagnostics application of rare biomarkers is a primary driver of market growth, as these markers play a crucial role in identifying and monitoring rare diseases. The ability to detect rare conditions early through accurate biomarker analyses significantly enhances patient outcomes. Advanced diagnostic techniques, including next-generation sequencing and proteomics, are increasingly employed to analyze specimens for rare biomarkers. These innovations facilitate the identification of disease-specific biomarkers, contributing to individualized treatment plans. The ongoing research efforts to discover new biomarkers further solidify the diagnostic applications of rare biomarkers, thereby expanding their utility in clinical settings.

Drug Development:

Rare biomarkers hold significant importance in the drug development process, as they can provide insights into drug efficacy and safety. By identifying specific biomarkers associated with rare diseases, pharmaceutical companies can tailor their drug development programs to target these pathways effectively. Biomarkers serve as critical endpoints in clinical trials, enabling researchers to assess the impact of new drugs on disease progression. The increasing investment in rare disease drug development, coupled with regulatory support for expedited approval processes, is driving the demand for rare biomarkers in this application segment. As precision medicine continues to evolve, the role of rare biomarkers in drug development is expected to expand further.

Research:

Research applications of rare biomarkers play a vital role in expanding the understanding of various diseases and conditions. Researchers utilize these biomarkers to explore disease mechanisms, identify therapeutic targets, and develop novel treatments. The integration of advanced technologies in biomarker research, such as high-throughput screening and bioinformatics, is enhancing the capability to discover and validate new biomarkers. Collaborations between academic institutions and industry stakeholders in research initiatives are becoming increasingly common, fostering innovation in biomarker discovery. As the focus on rare diseases intensifies, research applications of rare biomarkers will continue to drive growth in this market segment.

By Collection Method

Blood Collection:

Blood collection is a cornerstone method for obtaining rare biomarkers, as it facilitates a comprehensive analysis of various biological components. This method typically involves venipuncture, followed by the use of specialized tubes to stabilize the sample for analysis. The advantages of blood collection include a wealth of information regarding cellular, biochemical, and molecular markers that can be indicative of rare diseases. Moreover, advancements in blood collection techniques, such as the development of minimally invasive sampling methods, are making it easier for patients. The continuous evolution of blood-based biomarker research is expected to drive further growth in this collection method segment.

Urine Collection:

Urine collection is a non-invasive method for obtaining biological specimens, making it particularly appealing for a wide range of applications in rare biomarker analysis. This collection method allows for the analysis of metabolites and other biomolecules that can indicate the presence of rare diseases. The ease of urine collection enhances patient compliance, especially in pediatric and elderly populations. Stabilization methods, such as chemical preservatives, are employed to ensure the integrity of urine samples during transportation and storage. The increasing recognition of urinary biomarkers and their potential for early diagnosis is propelling the growth of this collection method in the market.

Saliva Collection:

Saliva collection is gaining traction as a convenient and non-invasive method for obtaining rare biomarkers. This method allows for the assessment of various biomarkers that reflect systemic health, making it particularly useful in monitoring rare conditions. The simplicity of saliva collection facilitates widespread use in both clinical and research settings. Stabilization techniques for saliva specimens are crucial to maintaining biomarker integrity until analysis can take place. As research continues to uncover the diagnostic potential of saliva-based biomarkers, the saliva collection method is expected to become more prevalent in the market, driving its growth.

Tissue Biopsy:

Tissue biopsy collection is essential for obtaining rare biomarkers that provide insights into the cellular and molecular basis of diseases. This method typically involves the surgical removal of a small tissue sample, which is then analyzed to detect specific biomarkers associated with rare diseases. While tissue collection can be invasive, it yields highly valuable information that is critical for diagnosing and understanding rare conditions. Proper stabilization methods, such as cryopreservation, are necessary to preserve tissue integrity for subsequent analysis. The increasing prevalence of cancer and other rare conditions that require tissue analysis is expected to drive demand for this collection method in the market.

Breath Sampling:

Breath sampling is an innovative and non-invasive method for collecting rare biomarkers, utilizing volatile organic compounds (VOCs) present in exhaled breath. This method is particularly appealing due to its simplicity and the minimal discomfort it causes patients. Breath analysis has shown promise in the early detection of various diseases, including certain rare conditions, by identifying unique VOC patterns. While the field is still developing, advances in sensor technologies and analytical techniques are enhancing the reliability of breath sampling. As research progresses and more applications are identified, breath sampling is expected to gain traction in the rare biomarkers specimen collection market.

By Stabilization Method

Temperature Control:

Temperature control is a crucial stabilization method for preserving the integrity of rare biomarkers during collection and transport. Maintaining optimal temperature conditions prevents degradation and ensures that biomarkers remain viable for analysis. This method is particularly important for biological samples, such as blood and tissue, which can be sensitive to temperature fluctuations. The use of refrigerated transport containers and temperature monitoring devices are common practices to ensure compliance with stabilization requirements. As the need for accurate biomarker analysis increases, the adoption of temperature control methods is expected to grow significantly.

Chemical Stabilization:

Chemical stabilization involves the use of preservatives and stabilizing agents to maintain the integrity of rare biomarkers in biological specimens. This method is essential for preventing enzymatic degradation and preserving the analytes of interest during transportation and storage. Various chemical agents can be employed depending on the type of specimen and the biomarkers being targeted. The increasing utilization of chemical stabilization methods is driven by the need for reliable biomarker analysis in clinical and research settings. This stabilization approach is particularly relevant for urine and saliva samples, where maintaining biomarker stability is critical for accurate results.

Lyophilization:

Lyophilization, or freeze-drying, is an effective stabilization method for preserving rare biomarkers by removing moisture from biological specimens. This process enhances the shelf-life of samples, making them easier to transport and store without the risk of degradation. Lyophilized samples can be reconstituted when needed, allowing for flexible analysis options. The growing focus on biobanking and the need for long-term storage solutions have increased the adoption of lyophilization techniques in the market. As research into rare biomarkers expands, the demand for lyophilization is expected to rise, driven by its advantages in sample preservation.

Freeze Drying:

Freeze drying is a specialized form of lyophilization that involves the removal of water from biological specimens at low temperatures, ensuring minimal damage to the structural integrity of the biomarkers. This stabilization method is particularly beneficial for sensitive analytes that may be prone to degradation during conventional storage methods. The use of freeze-dried samples facilitates long-term storage and easy transportation, making them ideal for research and diagnostics. As the focus on preserving rare biomarkers for future analysis increases, freeze drying is anticipated to gain traction in the specimen stabilization market, yielding significant growth opportunities.

Desiccation:

Desiccation is a stabilization method that involves drying biological specimens to remove moisture, thereby preventing microbial growth and enzymatic activity that could compromise biomarker integrity. This method is particularly effective for solid tissues and some biological fluids, where moisture content can significantly impact sample quality. Desiccated samples can be stored at room temperature, making them convenient for transport and storage in resource-limited settings. The increasing awareness of the need for quality control in biomarker analysis is driving the adoption of desiccation techniques, leading to growth in this segment of the market.

By Region

The North American region is expected to dominate the Rare Biomarkers Specimen Collection and Stabilization Market, accounting for approximately 40% of the total market share by 2035, driven by a robust healthcare infrastructure and significant investments in research and development activities. The increasing prevalence of rare diseases and government initiatives aimed at promoting personalized medicine are also contributing to market growth in this region. Furthermore, the presence of key industry players and ongoing collaborations between academic institutions and pharmaceutical companies are anticipated to enhance the development of innovative diagnostic tools that leverage rare biomarkers. The North American market is expected to witness a CAGR of 12% over the forecast period, underscoring its leading position.

In Europe, the Rare Biomarkers Specimen Collection and Stabilization Market is projected to hold around 30% of the total market share by 2035. The region's growth is attributed to the increasing focus on precision medicine and a favorable regulatory environment that encourages biomarker research and development. The rising incidence of rare diseases and the growing demand for advanced diagnostic tools are further fueling market expansion in Europe. Additionally, active participation from European research institutions and healthcare organizations in biomarker studies is expected to boost the market. The Asia Pacific region is also showing significant potential, accounting for around 20% of the market share. Rapid advancements in healthcare infrastructure, coupled with rising investments in biopharmaceutical research, are likely to propel growth in this area as well.

Opportunities

The Rare Biomarkers Specimen Collection and Stabilization Market presents numerous opportunities for growth, particularly in the realm of technological advancements. The emergence of novel analytical techniques, such as next-generation sequencing and mass spectrometry, allows for more accurate and efficient biomarker analysis. This progress not only enhances the reliability of diagnostic tests but also lowers costs associated with specimen collection and processing. As researchers continue to uncover new rare biomarkers, opportunities arise for the development of targeted therapeutics, ultimately improving patient outcomes. Furthermore, the ongoing collaboration between academia and industry leaders is paving the way for innovation in biomarker research, stimulating growth across the market.

Another significant opportunity lies in the expansion of the biobanking sector. As the global demand for rare disease research continues to grow, biobanks are becoming essential repositories for specimens that can be utilized in future studies. Establishing international collaborations for biobanking initiatives can enhance the availability of rare biomarker specimens, facilitating research and development efforts. Moreover, the rise of personalized medicine is driving the need for more diverse sample collections, highlighting the importance of collecting and stabilizing various biomarker types. This trend not only supports the development of tailored therapies but also fosters greater patient engagement in the research process, creating a positive feedback loop for market growth.

Threats

Despite the promising outlook for the Rare Biomarkers Specimen Collection and Stabilization Market, several threats could impede its growth. One such challenge is the complexity of regulatory approval processes for new biomarker tests. The stringent requirements set by regulatory bodies can delay the introduction of innovative diagnostic tools into the market, restricting timely access to new treatments for patients with rare diseases. Additionally, the variability in specimen collection and stabilization methods across different laboratories may lead to inconsistencies in biomarker analysis, potentially undermining the reliability of test results. This variability is particularly concerning given the critical role that biomarker analysis plays in guiding treatment decisions for patients with rare conditions.

Another significant threat is the high cost associated with the development and implementation of advanced biomarker analysis technologies. The financial burden may deter smaller research institutions and startups from investing in the necessary infrastructure, limiting their ability to contribute to the market. Furthermore, the rapid pace of technological advancements could lead to market saturation, with an overwhelming number of tests and products available. This saturation may create confusion among healthcare providers and patients, impacting the adoption of new biomarkers and slowing progress in the field. To mitigate these threats, stakeholders must focus on improving collaboration, standardizing procedures, and addressing regulatory challenges to ensure the continued growth of the Rare Biomarkers Specimen Collection and Stabilization Market.

Competitor Outlook

• Roche Diagnostics
• Thermo Fisher Scientific
• Illumina, Inc.
• Bio-Rad Laboratories, Inc.
• Qiagen N.V.
• SABiosciences (part of Qiagen)
• PerkinElmer, Inc.
• Beckman Coulter, Inc.
• Agilent Technologies, Inc.
• GE Healthcare
• Merck KGaA
• Abbott Laboratories
• Zymo Research Corporation
• Exact Sciences Corporation
• Promega Corporation

The competitive landscape of the Rare Biomarkers Specimen Collection and Stabilization Market is characterized by a diverse range of players, including established companies and emerging startups. Major players are continuously investing in research and development to enhance their product offerings and maintain a competitive edge. Collaborations and partnerships are also prevalent, as companies seek to leverage each other's expertise to accelerate innovation in biomarker research. The strategies employed by these companies often include expanding their product portfolios, entering new markets, and acquiring smaller firms with complementary technologies.

Roche Diagnostics is a key player in the market, known for its extensive range of diagnostic products and expertise in biomarker analysis. The company invests heavily in R&D to develop cutting-edge technologies that facilitate specimen collection and stabilization. Similarly, Thermo Fisher Scientific has a strong presence in the biomarker space, offering a wide array of solutions for sample processing and analysis. The company's focus on innovation and customer satisfaction has positioned it as a leader in the market. Illumina, Inc. is another prominent player, particularly recognized for its advancements in next-generation sequencing technologies, which are pivotal in rare biomarker research.

Emerging companies, such as Zymo Research Corporation and Exact Sciences Corporation, are also making their mark in the Rare Biomarkers Specimen Collection and Stabilization Market. These companies are focusing on developing unique technologies and solutions that address specific challenges in specimen collection and stabilization. For instance, Zymo Research is known for its innovative preservation technologies, while Exact Sciences specializes in cancer diagnostics, leveraging biomarkers for early detection. The competitive landscape is expected to evolve as new players enter the market and existing companies expand their capabilities, ultimately fostering an environment of innovation and collaboration in the pursuit of advancing rare disease diagnosis and treatment.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Merck KGaA
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Qiagen N.V.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 GE Healthcare
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Illumina, Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 PerkinElmer, Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Roche Diagnostics
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Abbott Laboratories
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Promega Corporation
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Beckman Coulter, Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Thermo Fisher Scientific
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Zymo Research Corporation
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Agilent Technologies, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Bio-Rad Laboratories, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Exact Sciences Corporation
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 SABiosciences (part of Qiagen)
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Rare Biomarkers Specimen Collection And Stabilization Market, By Application
    • 6.1.1 Diagnostics
    • 6.1.2 Drug Development
    • 6.1.3 Research
  • 6.2 Rare Biomarkers Specimen Collection And Stabilization Market, By Product Type
    • 6.2.1 Blood-based Rare Biomarkers
    • 6.2.2 Urine-based Rare Biomarkers
    • 6.2.3 Saliva-based Rare Biomarkers
    • 6.2.4 Tissue-based Rare Biomarkers
    • 6.2.5 Breath-based Rare Biomarkers
  • 6.3 Rare Biomarkers Specimen Collection And Stabilization Market, By Collection Method
    • 6.3.1 Blood Collection
    • 6.3.2 Urine Collection
    • 6.3.3 Saliva Collection
    • 6.3.4 Tissue Biopsy
    • 6.3.5 Breath Sampling
  • 6.4 Rare Biomarkers Specimen Collection And Stabilization Market, By Stabilization Method
    • 6.4.1 Temperature Control
    • 6.4.2 Chemical Stabilization
    • 6.4.3 Lyophilization
    • 6.4.4 Freeze Drying
    • 6.4.5 Desiccation

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Rare Biomarkers Specimen Collection And Stabilization Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Rare Biomarkers Specimen Collection And Stabilization market is categorized based on

By Product Type

• Blood-based Rare Biomarkers
• Urine-based Rare Biomarkers
• Saliva-based Rare Biomarkers
• Tissue-based Rare Biomarkers
• Breath-based Rare Biomarkers

By Application

• Diagnostics
• Drug Development
• Research

By Collection Method

• Blood Collection
• Urine Collection
• Saliva Collection
• Tissue Biopsy
• Breath Sampling

By Stabilization Method

• Temperature Control
• Chemical Stabilization
• Lyophilization
• Freeze Drying
• Desiccation

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Roche Diagnostics
• Thermo Fisher Scientific
• Illumina, Inc.
• Bio-Rad Laboratories, Inc.
• Qiagen N.V.
• SABiosciences (part of Qiagen)
• PerkinElmer, Inc.
• Beckman Coulter, Inc.
• Agilent Technologies, Inc.
• GE Healthcare
• Merck KGaA
• Abbott Laboratories
• Zymo Research Corporation
• Exact Sciences Corporation
• Promega Corporation